[Diagnostic and therapeutic applications of intracavernous injection of vasoactive drugs in impotence. Defense for the use of facilitating drugs. Part I--Pharmacology, classification and complications of active drugs].
The article discusses drugs which promote erection when injected via the intracavernous (IC) route during consultation. The diagnostic and therapeutic applications in the treatment of impotence are discussed also. 25% of impotent patients noted an improvement after this treatment while 50% of patients suffering from impotence of psychological origin noted an improvement. Auto-injection is also discussed. IC treatment now seems justified in most cases which have not responded to traditional therapeutic approaches and this includes cases of psychological origin. Vasoactive drugs can be described as being inducers (use of these drugs induces a rigid erection, even in the presence of the doctor), facilitating drugs (which produce a rigid erection only if sexual stimulation is present also) and inhibitors (which stop the erection). The former group (which has papaverine as leader) produces a significant number of side effects, not least of these being priapism; there is a risk of lasting iatrogenic impotence which is not negligible. These risks are reduced considerably when one uses facilitating drugs which, although less powerful, suffice in treating a large proportion of cases of impotence. Papaverine can not be replaced as a diagnostic drug but facilitating drugs should be used first in therapy and inducers should be used only if these facilitating drugs have failed.
Buvat
J
J
Association pour l'Etude de la Pathologie de l'Appareil Reproducteur et de la Psychosomatique (EPARP), Lille.
Buvat-Herbaut
M
M
Lemaire
A
A
Marcolin
G
G
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D010208:Papaverine / Q000008:administration & dosage / Q000009:adverse effects; D010643:Phenoxybenzamine / Q000008:administration & dosage / Q000009:adverse effects; D011317:Priapism / Q000139:chemically induced / Q000517:prevention & control / Q000628:therapy; D011458:Prostaglandins E / Q000008:administration & dosage; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage
D000317:Adrenergic alpha-Antagonists; D011458:Prostaglandins E; D010643:Phenoxybenzamine; D014660:Vasoactive Intestinal Peptide; D010208:Papaverine
Applications diagnostiques et thérapeutiques des injections intracaverneuses (IC) de drogues vasoactives dans l'impuissance. Plaidoyer pour l'utilisation des drogues facilitatrices. Partie I--Pharmacologie, classification et complications des drogues actives.